GeneDx Holdings Corp. Class A (WGS)

GeneDx Holdings Corp. stock has experienced significant positive momentum in the past six months, with the stock surging over 100% in the past year and approximately 70% year-to-date. This is due to strong earnings performance, with the company consistently surpassing analyst expectations for revenue and EPS in Q1, Q2, and Q3 of 2025. The company raised its full-year 2025 revenue guidance to between $425 million and $428 million. GeneDx received FDA Breakthrough Device Designation for its whole genome and exome tests for diagnosing symptomatic patients with life-threatening diseases or genetic disorders, providing an expedited regulatory review process. The stock has received numerous "Buy" and "Overweight" ratings from analysts, with price targets being increased. GeneDx was selected by Florida State University as a partner for the Sunshine Genetics Act, launching the nation's first state-backed genomic newborn screening program. There have been some corporate insider sell-offs, which have occasionally dampened investor sentiment. A sequential dip in test volumes in Q1 2025 was attributed to seasonality, adverse weather, and one fewer business day, though the company maintained robust fundamentals and expected stronger performance in the second half of the year.

Demand for GeneDx Holdings Corp.'s products and services exhibits seasonality. The company experienced a sequential dip in test volumes during Q1 2025, which management attributed to typical seasonality, adverse weather conditions, and one fewer business day. However, the second half of the year is generally expected to be seasonally stronger, and the company has reaffirmed its full-year volume growth expectations.

GeneDx Holdings Corp. is a genomics company focused on transforming healthcare through genetic testing and interpretation. The company specializes in genetic testing services, particularly in pediatric and rare disease diagnostics, with major products including ExomeDx and GenomeDx, which offer whole exome and genome sequencing. GeneDx also develops Centrellis, an AI-based health intelligence platform, to analyze clinical and genomic data. The company operates within the Healthcare sector, specifically in the Diagnostics & Research or Medical Services industry and was formerly known as Sema4 Holdings Corp.

GeneDx Holdings Corp. is based in Stamford, Connecticut, and its operations are primarily concentrated within the U.S. market. The company has also launched a nationwide hormone testing service.

GeneDx Holdings Corp. has maintained a strong and positive brand reputation over the past year. The company was named one of Fast Company's Most Innovative Companies of 2025, and Katherine Stueland, President and CEO of GeneDx, was recognized as a CNBC Changemaker in 2025. The FDA's granting of Breakthrough Device Designation for its genomic tests significantly enhances the company's credibility. The partnership with Florida State University to launch a state-backed genomic newborn screening program further solidifies its reputation as a leader in genomic diagnostics. While Weiss Ratings issued a "sell" rating on the stock, this primarily reflects a stock performance outlook rather than a direct impact on the company's operational brand reputation.

GeneDx Holdings Corp. has a diverse ownership structure. Institutional investors hold approximately 18.07% to 27.45% of the company's stock, while insiders own about 49.02%, and public companies and individual investors hold between 9.37% and 23.53%. Major institutional owners include Casdin Capital, LLC, Corvex Management LP, William Blair Investment Management, Llc, BlackRock, Inc., Pentwater Capital Management LP, Vanguard Group Inc, Goldman Sachs Group Inc, T. Rowe Price Investment Management, Inc., and UBS Group AG. Eli Casdin is noted as owning the most shares of GeneDx Holdings.